2023
DOI: 10.1002/epd2.20146
|View full text |Cite
|
Sign up to set email alerts
|

Thirteen years of experience with eslicarbazepine acetate in the United Kingdom and Republic of Ireland: A safety perspective

Abstract: ObjectiveEslicarbazepine acetate (ESL) is a once‐daily oral antiseizure medication. Its safety and tolerability from clinical trials have been mostly confirmed by real‐world data. The main purpose of this report is to provide an overview of the safety profile of ESL in the United Kingdom (UK) and Republic of Ireland (ROI).MethodsSafety data was obtained from UK and ROI post‐marketing sources (October 2009 – April 2022) by the Marketing Authorisation Holder. All individual reports were included in the Argus Saf… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
references
References 30 publications
0
0
0
Order By: Relevance